drugset

drugset / Trial / NCT00610428

Staccato Prochlorperazine in Migraine (in Clinic)

NCT00610428 ↗

Phase 2 Completed 75 enrolled Alexza Pharmaceuticals, Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Development of Staccato Prochlorperazine for the treatment of migraine headache.

Timeline

Start: 2005-03
Primary completion: 2005-10
Completion: 2005-10

Publications

Background Avram MJ, Spyker DA, Henthorn TK, Cassella JV. The pharmacokinetics and bioavailability of prochlorperazine delivered as a thermally generated aerosol in a single breath to volunteers. Clin Pharmacol Ther. 2009 Jan;85(1):71-7. doi: 10.1038/clpt.2008.184. Epub 2008 Oct 1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Prochlorperazine	Small molecule	5 mg	Inhaled
Subject	Prochlorperazine	Small molecule	10 mg	Inhaled

Indications